245 results on '"Rosenfield, RL"'
Search Results
2. The Diagnosis of Polycystic Ovary Syndrome during Adolescence
- Author
-
Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibañez-Toda L, Pena A, Horikawa R, Gomez-Lobo V, Joel D, Tfayli H, Arslanian S, Dabdghao P, Garcia Rudaz C, and Lee PA
- Published
- 2015
3. Consensus statement on the use of gonadotropin-releasing hormone analogs in children
- Author
-
Carel, Jc, Eugster, Ea, Rogol, A, Ghizzoni, Lucia, Palmert, Mr, ESPE LWPES GnRH Analogs Consensus Conference Group, Antoniazzi, F, Berenbaum, S, Bourguignon, Jp, Chrousos, Gp, Coste, J, Deal, S, de Vries, L, Foster, C, Heger, S, Holland, J, Jahnukainen, K, Juul, A, Kaplowitz, P, Lahlou, N, Lee, Mm, Lee, P, Merke, Dp, Neely, Ek, Oostdijk, W, Phillip, M, Rosenfield, Rl, Shulman, D, Styne, D, Tauber, M, Wit, J. M., Diabète de l'enfant et développement ((U 690)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Centre de Référence des Maladies Endocriniennes de la Croissance, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Section of Pediatric Endocrinology, Department of Pediatrics, Indiana University [Bloomington], Indiana University System-Indiana University System-Riley Hospital for Children, Division of Endocrinology, Department of Pediatrics, University of Virginia [Charlottesville], Centro per gli Stati Disendocrini e Dismetabolici, University of Parma = Università degli studi di Parma [Parme, Italie], Division of Endocrinology, Hospital for Sick Children, Department of Pediatrics, University of Toronto, Dr Carel has received grant funding from Ipsen and Takeda, Carel, Jean-Claude, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Virginia, and Università degli studi di Parma = University of Parma (UNIPR)
- Subjects
MESH: Organ Size ,Puberty, Precocious ,Gonadotropin-releasing hormone ,MESH: Hypothyroidism ,Gonadotropin-Releasing Hormone ,Nafarelin ,0302 clinical medicine ,Bone Density ,MESH: Child ,MESH: Gonadotropin-Releasing Hormone ,Child ,MESH: Puberty, Precocious ,MESH: Bone Density ,MESH: Nafarelin ,Organ Size ,GnRH analogs ,16. Peace & justice ,3. Good health ,MESH: Uterus ,Female ,Luteinizing hormone ,Psychosocial ,Polycystic Ovary Syndrome ,medicine.drug ,MESH: Ovary ,medicine.medical_specialty ,Adolescent ,Pediatric endocrinology ,030209 endocrinology & metabolism ,precocious puberty ,03 medical and health sciences ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Hypothyroidism ,030225 pediatrics ,MESH: Body Height ,MESH: Luteinizing Hormone ,medicine ,Humans ,Precocious puberty ,Gynecology ,MESH: Adolescent ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,MESH: Humans ,business.industry ,Histrelin ,Public health ,Ovary ,Uterus ,Luteinizing Hormone ,medicine.disease ,Body Height ,Family medicine ,Pediatrics, Perinatology and Child Health ,MESH: Polycystic Ovary Syndrome ,business ,MESH: Female - Abstract
OBJECTIVE. Gonadotropin-releasing hormone analogs revolutionized the treatment of central precocious puberty. However, questions remain regarding their optimal use in central precocious puberty and other conditions. The Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology convened a consensus conference to review the clinical use of gonadotropin-releasing hormone analogs in children and adolescents.PARTICIPANTS. When selecting the 30 participants, consideration was given to equal representation from North America (United States and Canada) and Europe, an equal male/female ratio, and a balanced spectrum of professional seniority and expertise.EVIDENCE. Preference was given to articles written in English with long-term outcome data. The US Public Health grading system was used to grade evidence and rate the strength of conclusions. When evidence was insufficient, conclusions were based on expert opinion.CONSENSUS PROCESS. Participants were put into working groups with assigned topics and specific questions. Written materials were prepared and distributed before the conference, revised on the basis of input during the meeting, and presented to the full assembly for final review. If consensus could not be reached, conclusions were based on majority vote. All participants approved the final statement.CONCLUSIONS. The efficacy of gonadotropin-releasing hormone analogs in increasing adult height is undisputed only in early-onset (girls
- Published
- 2009
4. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries.
- Author
-
Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA, Rosenfield, Robert L, Wroblewski, Kristen, Padmanabhan, Vasantha, Littlejohn, Elizabeth, Mortensen, Monica, and Ehrmann, David A
- Abstract
Objective: To determine the relationship of antimüllerian hormone (AMH) levels to polycystic ovaries and ovarian androgenic function.Design: Prospective case-control study.Setting: General clinical research center.Participant(s): Eumenorrheic asymptomatic volunteers without (V-NO; n = 19; reference population) or with (V-PCO; n = 28) a polycystic ovary and hyperandrogenemic anovulatory subjects grouped according to ovarian function into typical PCOS (PCOS-T; n = 37) and atypical PCOS (PCOS-A; n = 18).Intervention(s): Pelvic ultrasonography, short dexamethasone androgen-suppression test (SDAST), and GnRH agonist (GnRHag) test.Main Outcome Measure(s): Baseline AMH levels were related to polycystic ovary status, testosterone response to SDAST, and 17-hydroxyprogesterone response to GnRHag test.Result(s): AMH levels correlated with SDAST and GnRHag test outcomes. AMH was elevated (>6.2 ng/mL) in 32% of V-PCO versus 5% V-NO. The 21% of V-PCO who met Rotterdam PCOS criteria all had functional ovarian hyperandrogenism, but AMH levels were similar to nonhyperandrogenic V-PCO. AMH >10.7 ng/mL discriminated V-PCO from PCOS with 96% specificity and 41% sensitivity for PCOS-T, and insignificantly for PCOS-A.Conclusion(s): AMH levels are independently related to ovarian androgenic function and polycystic ovaries. Very high AMH levels are specific but insensitive for PCOS. In the absence of hyperandrogenism, moderate AMH elevation in women with normal-variant polycystic ovaries seems to indicate an enlarged oocyte pool. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
5. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index [corrected] [published erratum appears in PEDIATRICS 2009 Apr;123(4):1255].
- Author
-
Rosenfield RL, Lipton RB, and Drum ML
- Abstract
BACKGROUND: The early onset of puberty may be related to obesity, so there is a need to know the prevalence of early pubertal milestones in nonoverweight children. OBJECTIVE. We compared attainment of stage 2 breasts, stage 3 (sexual) pubic hair, and menarche in the Third National Health and Nutrition Examination Survey sample of children with normal BMI with those with excessive BMI (> or =85th percentile). DESIGN/METHODS: The ages at which 5%, 50%, and 95% of youth had attained key pubertal stages were estimated by probit models. Logit models were then fit to compare attainment of these milestones in children of excessive and normal BMI. RESULTS: Pubertal signs occurred before 8.0 years of age in <5% of the normal-BMI general and non-Hispanic white female population. However, pubertal milestones generally appeared earlier in normal-BMI non-Hispanic black and Mexican American girls; thelarche occurred before age 8.0 in 12% to 19% of these groups, and the 5th percentile for menarche was 0.8 years earlier for non-Hispanic black than non-Hispanic white subjects. Pubarche was found in < or =3% of 8.0-year-old girls with normal BMI of all of these ethnic groups but was significantly earlier in minority groups. Pubarche appeared before 10.0 years in <2% of normal-BMI boys. Girls with excessive BMI had a significantly higher prevalence of breast appearance from ages 8.0 through 9.6 years and pubarche from ages 8.0 through 10.2 years than those with normal BMI. Menarche was also significantly more likely to occur in preteen girls with an elevated BMI. CONCLUSIONS: Prevalence estimates are given for the key pubertal milestones in children with normal BMI. Breast and sexual pubic hair development are premature before 8 years of age in girls with normal BMI in the general population. Adiposity and non-Hispanic black and Mexican American ethnicity are independently associated with earlier pubertal development in girls. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
6. Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome
- Author
-
Rosenfield, RL, primary, Barnes, RB, additional, Cara, JF, additional, and Lucky, AW, additional
- Published
- 1991
- Full Text
- View/download PDF
7. Clinical practice. Hirsutism.
- Author
-
Rosenfield RL
- Published
- 2005
8. Selective retention and formation of a delta5-androstenediol-receptor complex in cell nuclei of the rat vagina.
- Author
-
Shao, TC, primary, Castañeda, E, additional, Rosenfield, RL, additional, and Liao, S, additional
- Published
- 1975
- Full Text
- View/download PDF
9. Hirsutism.
- Author
-
Willenberg HS, Bahlo M, Scherbaum WA, de Zegher F, Dunger DB, Ibáñez L, and Rosenfield RL
- Published
- 2006
10. Letter to the Editor From Rosenfield, et al: "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome".
- Author
-
Rosenfield RL, Martin KA, Chang RJ, Ehrmann DA, Lobo RA, and Pugeat MM
- Subjects
- Humans, Female, Polycystic Ovary Syndrome therapy, Polycystic Ovary Syndrome diagnosis, Practice Guidelines as Topic, Evidence-Based Medicine standards
- Published
- 2024
- Full Text
- View/download PDF
11. The Search for the Causes of Common Hyperandrogenism, 1965 to Circa 2015.
- Author
-
Rosenfield RL
- Subjects
- Humans, Female, History, 20th Century, History, 21st Century, Adrenarche physiology, Androgens metabolism, Hyperandrogenism metabolism, Polycystic Ovary Syndrome metabolism
- Abstract
From 1965 to 2015, immense strides were made into understanding the mechanisms underlying the common androgen excess disorders, premature adrenarche and polycystic ovary syndrome (PCOS). The author reviews the critical discoveries of this era from his perspective investigating these disorders, commencing with his early discoveries of the unique pattern of plasma androgens in premature adrenarche and the elevation of an index of the plasma free testosterone concentration in most hirsute women. The molecular genetic basis, though not the developmental biologic basis, for adrenarche is now known and 11-oxytestosterones shown to be major bioactive adrenal androgens. The evolution of the lines of research into the pathogenesis of PCOS is historically traced: research milestones are cited in the areas of neuroendocrinology, insulin resistance, hyperinsulinism, type 2 diabetes mellitus, folliculogenesis, androgen secretion, obesity, phenotyping, prenatal androgenization, epigenetics, and complex genetics. Large-scale genome-wide association studies led to the 2014 discovery of an unsuspected steroidogenic regulator DENND1A (differentially expressed in normal and neoplastic development). The splice variant DENND1A.V2 is constitutively overexpressed in PCOS theca cells in long-term culture and accounts for their PCOS-like phenotype. The genetics are complex, however: DENND1A intronic variant copy number is related to phenotype severity, and recent data indicate that rare variants in a DENND1A regulatory network and other genes are related to PCOS. Obesity exacerbates PCOS manifestations via insulin resistance and proinflammatory cytokine excess; excess adipose tissue also forms testosterone. Polycystic ovaries in 40 percent of apparently normal women lie on the PCOS functional spectrum. Much remains to be learned., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
12. Normal and Premature Adrenarche.
- Author
-
Rosenfield RL
- Subjects
- Androgens, Child, Child, Preschool, Female, Humans, Adrenal Hyperplasia, Congenital complications, Adrenarche physiology, Polycystic Ovary Syndrome, Puberty, Precocious complications, Puberty, Precocious diagnosis
- Abstract
Adrenarche is the maturational increase in adrenal androgen production that normally begins in early childhood. It results from changes in the secretory response to adrenocorticotropin (ACTH) that are best indexed by dehydroepiandrosterone sulfate (DHEAS) rise. These changes are related to the development of the zona reticularis (ZR) and its unique gene/enzyme expression pattern of low 3ß-hydroxysteroid dehydrogenase type 2 with high cytochrome b5A, sulfotransferase 2A1, and 17ß-hydroxysteroid dehydrogenase type 5. Recently 11-ketotestosterone was identified as an important bioactive adrenarchal androgen. Birth weight, body growth, obesity, and prolactin are related to ZR development. Adrenarchal androgens normally contribute to the onset of sexual pubic hair (pubarche) and sebaceous and apocrine gland development. Premature adrenarche causes ≥90% of premature pubarche (PP). Its cause is unknown. Affected children have a significantly increased growth rate with proportionate bone age advancement that typically does not compromise growth potential. Serum DHEAS and testosterone levels increase to levels normal for early female puberty. It is associated with mildly increased risks for obesity, insulin resistance, and possibly mood disorder and polycystic ovary syndrome. Between 5% and 10% of PP is due to virilizing disorders, which are usually characterized by more rapid advancement of pubarche and compromise of adult height potential than premature adrenarche. Most cases are due to nonclassic congenital adrenal hyperplasia. Algorithms are presented for the differential diagnosis of PP. This review highlights recent advances in molecular genetic and developmental biologic understanding of ZR development and insights into adrenarche emanating from mass spectrometric steroid assays., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
13. Letter to the Editor: "Glucocorticoid Resistance in Premature Adrenarche and PCOS: From Childhood to Adulthood".
- Author
-
Rosenfield RL
- Abstract
The conclusion of Panayiotopoulos et al. that glucocorticoid resistance accounted for 57% to 67% of their premature adrenarche and polycystic ovary syndrome cases cannot be accepted from the data presented. This is because proper validation of their method for determining glucocorticoid sensitivity is not presented. Furthermore, the method seems insensitive to physiologic glucocorticoid concentrations., (© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2020
- Full Text
- View/download PDF
14. Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence.
- Author
-
Rosenfield RL
- Subjects
- Adolescent, Female, Humans, Menstruation Disturbances, Polycystic Ovary Syndrome therapy, Practice Guidelines as Topic, Polycystic Ovary Syndrome diagnosis
- Abstract
Recommendations have been provided for the diagnosis and therapy of polycystic ovary syndrome in adolescence from 3 international expert conferences 2015-2018. Despite agreement about essentials, differences among details of these recommendations have engendered confusion. This commentary provides perspective about the agreements and disagreements among these recommendations and how these recommendations relate to other guidance. It concludes with practice suggestions that align with these recommendations., (Copyright © 2020 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
15. Current concepts of polycystic ovary syndrome pathogenesis.
- Author
-
Rosenfield RL
- Subjects
- Androgens, Anti-Mullerian Hormone, Female, Humans, Insulin, Death Domain Receptor Signaling Adaptor Proteins, Guanine Nucleotide Exchange Factors, Polycystic Ovary Syndrome genetics, Polycystic Ovary Syndrome pathology, Signal Transduction
- Abstract
Purpose of Review: This review provides a model for understanding polycystic ovary syndrome (PCOS) pathophysiology and updates the evidence on which it is based. Then, it highlights complimentary molecular genetic and epigenetic advances in understanding PCOS cause., Recent Findings: Important studies into PCOS cause built on the 2014 discovery of a novel regulatory protein variant that underlies the typical PCOS steroidogenic abnormalities: DENND1A.V2 (differentially expressed in normal and neoplastic development, isoform 1A, variant 2). Over 30 DENND1A gene variants have been found, the vast majority upstream of the coding sequence and potentially regulatory. These variants are individually uncommon but collectively plausibly cause 50% of PCOS. Anti-Müllerian hormone (AMH)/AMH receptor variants with decreased function possibly cause 6.7% of PCOS. DENNND1A was recently reported to belong to a signaling network that upregulates luteinizing hormone receptor expression and insulin mitogenic signaling. Prenatal androgen administration has proven to be a potent epigenetic regulator that causes transgenerational epigenomic changes in a mouse PCOS model with similarities to those in human PCOS and PCOS daughters., Summary: In addition to finding how gene variants contribute to PCOS pathogenesis, better understanding of androgen epigenetic mechanisms of action in diverse tissues can be expected to expand our understanding of PCOS pathogenesis.
- Published
- 2020
- Full Text
- View/download PDF
16. Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations.
- Author
-
Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, Sas TCJ, and Mauras N
- Subjects
- Age Factors, Child, Estrogens administration & dosage, Female, Humans, Time-to-Treatment, Turner Syndrome diagnosis, Estrogen Replacement Therapy methods, Estrogen Replacement Therapy standards, Turner Syndrome drug therapy
- Abstract
Context: Most girls with Turner syndrome (TS) have hypergonadotropic hypogonadism and need hormonal replacement for induction of puberty and then for maintaining secondary sex characteristics, attaining peak bone mass, and uterine growth. The optimal estrogen replacement regimen is still being studied., Evidence Acquisition: We conducted a systematic search of PubMed for studies related to TS and puberty., Evidence Synthesis: The goals of replacement are to mimic normal timing and progression of physical and social development while minimizing risks. Treatment should begin at age 11 to 12 years, with dose increases over 2 to 3 years. Initiation with low-dose estradiol (E2) is crucial to preserve growth potential. Delaying estrogen replacement may be deleterious to bone and uterine health. For adults who have undergone pubertal development, we suggest transdermal estrogen and oral progestin and discuss other approaches. We discuss linear growth, lipids, liver function, blood pressure, neurocognition, socialization, and bone and uterine health as related to hormonal replacement., Conclusion: Evidence supports the effectiveness of starting pubertal estrogen replacement with low-dose transdermal E2. When transdermal E2 is unavailable or the patient prefers, evidence supports use of oral micronized E2 or an intramuscular preparation. Only when these are unavailable should ethinyl E2 be prescribed. We recommend against the use of conjugated estrogens. Once progestin is added, many women prefer the ease of use of a pill containing both an estrogen and a progestin. The risks and benefits of different types of preparations, with examples, are discussed.
- Published
- 2018
- Full Text
- View/download PDF
17. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
- Author
-
Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugeat MM, and Rosenfield RL
- Subjects
- Androgen Antagonists therapeutic use, Androgens blood, Contraceptives, Oral, Combined therapeutic use, Evidence-Based Medicine methods, Female, Hirsutism etiology, Humans, Hypoglycemic Agents therapeutic use, Premenopause, Severity of Illness Index, Hair Removal methods, Hirsutism diagnosis, Hirsutism therapy
- Abstract
Objective: To update the "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline," published by the Endocrine Society in 2008., Participants: The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist., Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies., Consensus Process: Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines., Conclusion: We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.
- Published
- 2018
- Full Text
- View/download PDF
18. Letter to the Editor: "Normal Pubertal Development in Daughters of Women With PCOS: A Controlled Study".
- Author
-
Rosenfield RL
- Subjects
- Female, Humans, Nuclear Family, Testosterone, Polycystic Ovary Syndrome, Sexual Maturation
- Published
- 2017
- Full Text
- View/download PDF
19. The Effect of the Testis on the Ovary: Structure-Function Relationships in a Neonate with a Unilateral Ovotestis (Ovotesticular Disorder of Sex Development) .
- Author
-
Greeley SA, Littlejohn E, Husain AN, Waggoner D, Gundeti M, and Rosenfield RL
- Subjects
- Adult, Chromosomes, Human, Y genetics, Female, Humans, Infant, Newborn, Male, Mosaicism, Ovary metabolism, Ovary surgery, Ovotesticular Disorders of Sex Development genetics, Testis metabolism, Testis surgery, Anti-Mullerian Hormone blood, Estradiol blood, Ovotesticular Disorders of Sex Development blood, Ovotesticular Disorders of Sex Development surgery, Testosterone blood
- Abstract
Aims: To evaluate gonadal function in a newborn with suspected ovotesticular disorder of sex development (DSD)., Methods: Gonadal function was evaluated at baseline and after gonadotropin-releasing hormone agonist (GnRHag) stimulation testing., Results: A full-term 46,XX neonate with genital ambiguity produced serum testosterone and anti-Müllerian hormone (AMH) levels appropriate for males within days, while serum estradiol remained prepubertal, both spontaneously and in response to GnRHag stimulation testing. Ovotesticular DSD was diagnosed at laparoscopy: the left gonad was an ovotestis and the right gonad an ovary arrested at the primordial follicle stage of development. Mosaicism for an isochromosome of the Y short arm in 6-18% of gonadal cells was demonstrated. After ovotestis removal at 3 weeks of age, serum AMH became low within a month, but the elevated testosterone was slow to resolve, apparently from ovarian androgenic hyperfunction coincident with ovarian estrogenic hyperfunction and an adult degree of ovarian development. Ovarian morphology and function gradually normalized as neonatal minipuberty waned., Conclusions: In a neonate with genital ambiguity due to ovotesticular DSD, testicular AMH and testosterone production respectively appear to account for the initial arrest of ovarian development and subsequent rapid hyperfunction of the contralateral ovary after ovotestis removal. ., (© 2017 S. Karger AG, Basel.)
- Published
- 2017
- Full Text
- View/download PDF
20. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
- Author
-
Rosenfield RL and Ehrmann DA
- Subjects
- Androgens physiology, Animals, Female, Genome-Wide Association Study, Humans, Hyperandrogenism physiopathology, Hyperinsulinism complications, Insulin Resistance physiology, Polycystic Ovary Syndrome epidemiology, Polycystic Ovary Syndrome genetics, Hyperandrogenism complications, Ovary physiopathology, Polycystic Ovary Syndrome etiology
- Abstract
Polycystic ovary syndrome (PCOS) was hypothesized to result from functional ovarian hyperandrogenism (FOH) due to dysregulation of androgen secretion in 1989-1995. Subsequent studies have supported and amplified this hypothesis. When defined as otherwise unexplained hyperandrogenic oligoanovulation, two-thirds of PCOS cases have functionally typical FOH, characterized by 17-hydroxyprogesterone hyperresponsiveness to gonadotropin stimulation. Two-thirds of the remaining PCOS have FOH detectable by testosterone elevation after suppression of adrenal androgen production. About 3% of PCOS have a related isolated functional adrenal hyperandrogenism. The remaining PCOS cases are mild and lack evidence of steroid secretory abnormalities; most of these are obese, which we postulate to account for their atypical PCOS. Approximately half of normal women with polycystic ovarian morphology (PCOM) have subclinical FOH-related steroidogenic defects. Theca cells from polycystic ovaries of classic PCOS patients in long-term culture have an intrinsic steroidogenic dysregulation that can account for the steroidogenic abnormalities typical of FOH. These cells overexpress most steroidogenic enzymes, particularly cytochrome P450c17. Overexpression of a protein identified by genome-wide association screening, differentially expressed in normal and neoplastic development 1A.V2, in normal theca cells has reproduced this PCOS phenotype in vitro. A metabolic syndrome of obesity-related and/or intrinsic insulin resistance occurs in about half of PCOS patients, and the compensatory hyperinsulinism has tissue-selective effects, which include aggravation of hyperandrogenism. PCOS seems to arise as a complex trait that results from the interaction of diverse genetic and environmental factors. Heritable factors include PCOM, hyperandrogenemia, insulin resistance, and insulin secretory defects. Environmental factors include prenatal androgen exposure and poor fetal growth, whereas acquired obesity is a major postnatal factor. The variety of pathways involved and lack of a common thread attests to the multifactorial nature and heterogeneity of the syndrome. Further research into the fundamental basis of the disorder will be necessary to optimally correct androgen levels, ovulation, and metabolic homeostasis.
- Published
- 2016
- Full Text
- View/download PDF
21. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.
- Author
-
Rosenfield RL
- Subjects
- 17-alpha-Hydroxyprogesterone blood, Adolescent, Adult, Anovulation physiopathology, Female, Humans, Hyperandrogenism physiopathology, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome diagnosis, Ovary physiopathology, Polycystic Ovary Syndrome physiopathology
- Abstract
Background: Polycystic ovary syndrome (PCOS) is the most common cause of chronic hyperandrogenic anovulation. Two-thirds of PCOS patients have functionally typical PCOS, with typical functional ovarian hyperandrogenism manifest as 17-hydroxyprogesterone hyper-responsiveness to gonadotropin stimulation. Most, but not all, of the remainder have atypical functional ovarian hyperandrogenism. Many asymptomatic volunteers with polycystic ovary morphology (PCOM) have similar abnormalities., Objective: The objective of this paper is to review the relationship of biochemical ovarian function to the clinical spectrum observed in PCOS and in normal volunteers with PCOM., Findings: Adolescents and adults with PCOS are similar clinically and biochemically. Ninety-five percent of functionally typical PCOS have classic PCOS, ie, hyperandrogenic anovulation with PCOM. In addition to having more severe hyperandrogenism and a greater prevalence of PCOM than other PCOS, they have a significantly greater prevalence of glucose intolerance although insulin resistance is similarly reduced. Half of normal-variant PCOM have PCOS-related steroidogenic dysfunction, which suggests a PCOS carrier state., Conclusions: There is a spectrum of ovarian androgenic dysfunction that ranges from subclinical hyperandrogenemia in some normal-variant PCOM to severe ovarian hyperandrogenism in most classic PCOS. A minority of mild PCOS cases do not fall on this spectrum of ovarian androgenic dysfunction, but rather seem to have obesity as the basis of their hyperandrogenism, or, less often, isolated adrenal androgenic dysfunction. Half of normal-variant PCOM also do not fall on the PCOS spectrum, and some of these seem to have excessive folliculogenesis as a variant that may confer mild prolongation of the reproductive lifespan. Improved understanding of PCOM in young women is needed., (Copyright © 2015 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
22. The Diagnosis of Polycystic Ovary Syndrome in Adolescents.
- Author
-
Rosenfield RL
- Subjects
- Adolescent, Diagnosis, Differential, Female, Guidelines as Topic, Humans, Insulin Resistance, Polycystic Ovary Syndrome complications, Polycystic Ovary Syndrome therapy, Anovulation etiology, Hyperandrogenism etiology, Metabolic Syndrome etiology, Polycystic Ovary Syndrome diagnosis
- Abstract
Consensus has recently been reached by international pediatric subspecialty societies that otherwise unexplained persistent hyperandrogenic anovulation using age- and stage-appropriate standards are appropriate diagnostic criteria for polycystic ovary syndrome (PCOS) in adolescents. The purpose of this review is to summarize these recommendations and discuss their basis and implications. Anovulation is indicated by abnormal uterine bleeding, which exists when menstrual cycle length is outside the normal range or bleeding is excessive: cycles outside 19 to 90 days are always abnormal, and most are 21 to 45 days even during the first postmenarcheal year. Continued menstrual abnormality in a hyperandrogenic adolescent for 1 year prognosticates at least 50% risk of persistence. Hyperandrogenism is best indicated by persistent elevation of serum testosterone above adult norms as determined in a reliable reference laboratory. Because hyperandrogenemia documentation can be problematic, moderate-severe hirsutism constitutes clinical evidence of hyperandrogenism. Moderate-severe inflammatory acne vulgaris unresponsive to topical treatment is an indication to test for hyperandrogenemia. Treatment of PCOS is symptom-directed. Cyclic estrogen-progestin oral contraceptives are ordinarily the preferred first-line medical treatment because they reliably improve both the menstrual abnormality and hyperandrogenism. First-line treatment of the comorbidities of obesity and insulin resistance is lifestyle modification with calorie restriction and increased exercise. Metformin in conjunction with behavior modification is indicated for glucose intolerance. Although persistence of hyperandrogenic anovulation for ≥2 years ensures the distinction of PCOS from physiologic anovulation, early workup is advisable to make a provisional diagnosis so that combined oral contraceptive treatment, which will mask diagnosis by suppressing hyperandrogenemia, is not unnecessarily delayed., (Copyright © 2015 by the American Academy of Pediatrics.)
- Published
- 2015
- Full Text
- View/download PDF
23. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood.
- Author
-
Rosenfield RL, Ehrmann DA, and Littlejohn EE
- Subjects
- Adolescent, Adult, Age of Onset, Child, Female, Follow-Up Studies, Glucose Tolerance Test, Humans, Hyperandrogenism blood, Menstruation Disturbances blood, Menstruation Disturbances epidemiology, Menstruation Disturbances etiology, Ovarian Diseases blood, Ovarian Diseases complications, Ovarian Diseases epidemiology, Polycystic Ovary Syndrome blood, Testosterone blood, Young Adult, Hyperandrogenism complications, Hyperandrogenism epidemiology, Polycystic Ovary Syndrome epidemiology, Polycystic Ovary Syndrome etiology
- Abstract
Background: Menstrual irregularity and above-average testosterone levels in adolescence may presage polycystic ovary syndrome (PCOS) in adulthood but persist in only a minority. Prolonged anovulatory cycles in normal adolescents are associated with increased testosterone levels. Thus, questions have been raised about the accuracy of PCOS diagnosed in adolescents., Objective: The purpose of this study was to follow-up hyperandrogenic adolescents with features of PCOS to test the hypothesis that adolescent functional ovarian hyperandrogenism (FOH) persists into adulthood., Study Subjects: A series of adults previously reported to have adolescent PCOS, with most documented to have FOH by GnRH agonist or dexamethasone androgen-suppression test criteria, were recalled., Methods: Recall occurred >3 years after the initial diagnosis and at the age of >18.0 years. Respondents underwent examination, baseline androgen evaluation, and an oral glucose tolerance test after discontinuing oral contraceptive therapy., Results: Of the adolescent hyperandrogenic patients, 68% (15 of 22) were traceable, and 60% of those traced returned for follow-up, including half (n = 8) of the original FOH group. The baseline characteristics of respondents and nonrespondents were not significantly different. Patients with FOH were reevaluated when their mean age was 23.0 years (range, 18.4-29.4 years), gynecologic age was 10.7 years (range, 5.5-18.4 years), and body mass index was 42.3 kg/m(2) (range, 28.3-52.1 kg/m(2); P = .02 vs adolescence). Serum free testosterone was 24 pg/mL (range, 10-38 pg/mL, normal, 3-9 pg/mL; not significant vs adolescence); all were oligomenorrheic. Whereas 3 of 8 had impaired glucose tolerance as adolescents, at follow-up 6 of 8 had developed abnormal glucose tolerance (2 with type 2 diabetes mellitus)., Conclusions: Adolescents with FOH, which underlies most PCOS, uniformly have persistent hyperandrogenism, and glucose tolerance tends to deteriorate. Testing ovarian androgenic function in hyperandrogenic adolescents may be of prognostic value.
- Published
- 2015
- Full Text
- View/download PDF
24. Commentary: Launch of a quality improvement network for evidence-based management of uncommon pediatric endocrine disorders: Turner syndrome as a prototype.
- Author
-
Rosenfield RL, DiMeglio LA, Mauras N, Ross J, Shaw ND, Greeley SA, Haymond M, Rubin K, and Rhodes ET
- Subjects
- Adolescent, Algorithms, Child, Estrogen Replacement Therapy statistics & numerical data, Female, Humans, Rare Diseases therapy, Research Design, Community Networks organization & administration, Community Networks standards, Endocrine System Diseases therapy, Evidence-Based Practice organization & administration, Evidence-Based Practice standards, Quality Improvement organization & administration, Turner Syndrome therapy
- Abstract
Background: Traditional, hypothesis-oriented research approaches have thus far failed to generate sufficient evidence to achieve consensus about the management of children with many endocrine disorders, partly because of the rarity of these disorders and because of regulatory burdens unique to research in children., Objective: The Pediatric Endocrine Society is launching a quality improvement network in spring 2015 for the management of pediatric endocrine disorders that are relatively uncommon in any single practice and/or for which there is no consensus on management., Design: The first of the quality improvement programs to be implemented seeks to improve the care of 11- to 17-year-old girls with Turner syndrome who require initiation of estrogen replacement therapy by providing a standardized clinical assessment and management plan (SCAMP) for transdermal estradiol treatment to induce pubertal development. The SCAMP algorithm represents a starting point within current best practice that is meant to undergo refinement through an iterative process of analysis of deidentified data collected in the course of clinical care by a network of pediatric endocrinologists., Conclusion: It is anticipated that this program will not only improve care, but will also result in actionable data that will generate new research hypotheses and changes in management of pediatric endocrine disorders.
- Published
- 2015
- Full Text
- View/download PDF
25. Clinical review: Adolescent anovulation: maturational mechanisms and implications.
- Author
-
Rosenfield RL
- Subjects
- Adolescent, Anovulation physiopathology, Female, Humans, Menstruation Disturbances physiopathology, Ovary physiopathology, Pituitary Gland physiopathology, Polycystic Ovary Syndrome physiopathology, Anovulation etiology, Menstrual Cycle physiology, Menstruation Disturbances etiology, Polycystic Ovary Syndrome complications
- Abstract
Context: Adolescents are at high risk for menstrual dysfunction. The diagnosis of anovulatory disorders that may have long-term health consequences is too often delayed., Evidence Acquisition: A review of the literature in English was conducted, and data were summarized and integrated from the author's perspective., Main Findings: Normal adolescent anovulation causes only minor menstrual cycle irregularity: most cycles range from 21-45 days, even in the first postmenarcheal year, 90% by the fourth year. Approximately half of symptomatic menstrual irregularity is due to neuroendocrine immaturity, and half is associated with increased androgen levels. The former is manifest as aluteal or short/deficient luteal phase cycles and usually resolves spontaneously. The latter seems related to polycystic ovary syndrome because adolescent androgen levels are associated with adult androgens and ovulatory dysfunction, but data are sparse. Obesity causes hyperandrogenemia and, via unclear mechanisms, seems to suppress LH; it may mimic polycystic ovary syndrome. The role of pubertal insulin resistance in physiological adolescent anovulation is unclear. High-sensitivity gonadotropin and steroid assays, the latter by specialty laboratories, are necessary for accurate diagnosis of pubertal disorders. Polycystic ovaries are a normal ultrasonographic finding in young women and are associated with nearly 2-fold increased anti-Müllerian hormone levels. Oral contraceptives are generally the first-line treatment for ongoing menstrual dysfunction, and the effects of treatment are similar among preparations., Conclusions: Menstrual cycle duration persistently outside 21-45 days in adolescents is unusual, and persistence ≥ 1 year suggests that disordered hypothalamic-pituitary-gonadal function be considered. Research is needed on the mechanisms and prognosis of adolescent anovulation.
- Published
- 2013
- Full Text
- View/download PDF
26. Comparison of detection of normal puberty in girls by a hormonal sleep test and a gonadotropin-releasing hormone agonist test.
- Author
-
Rosenfield RL, Bordini B, and Yu C
- Subjects
- Adolescent, Age Determination by Skeleton methods, Body Mass Index, Child, Estradiol blood, Female, Follicle Stimulating Hormone blood, Health, Humans, Luteinizing Hormone blood, Polysomnography statistics & numerical data, Puberty blood, Sleep physiology, Diagnostic Techniques, Endocrine, Gonadotropin-Releasing Hormone agonists, Polysomnography methods, Puberty physiology
- Abstract
Context: The magnitude of sleep-related gonadotropin rise required to activate pubertal feminization is not established., Objective: The objective of the study was to determine the normal relationship of pubertal hormone responses to sleep and to GnRH agonist (GnRHag) challenge across the female pubertal transition., Design/setting: This was a prospective study in a General Clinical Research Center., Participants: Sixty-two healthy 6- to 13-year-old volunteer girls participated in the study., Interventions: Interventions included overnight blood sampling followed by GnRHag (leuprolide acetate) injection., Primary Outcome Variables: The primary outcome variables included LH, FSH, and estradiol., Results: LH levels rose steadily during sleep and after GnRHag throughout the prepubertal years. The LH response to sleep and GnRHag correlated well across groups (eg, r = 0.807, peak vs 4 h post-GnRHag value); however, this correlation was less robust than in boys (r = 0.964, P < .01). Sleep peak LH of 1.3 U/L or greater had 85% sensitivity and 2.1 U/L or greater 96% specificity for detecting puberty (thelarche). The LH 1-hour post-GnRHag value of 3.2 U/L or greater had 95% sensitivity and 5.5 U/L or greater 96% specificity for detecting puberty. Girls entered puberty at lower LH levels than boys. FSH levels rose day and night during the prepubertal years to reach 1.0 U/L or greater during puberty but discriminated puberty poorly. Estradiol of 34 pg/mL or greater at 20-24 hours after GnRHag was 95% sensitive and 60 pg/mL or greater was 95% specific for puberty. Thirty-six percent of overweight early pubertal girls had meager hormonal evidence of puberty., Conclusions: These data suggest that sleep-related pubertal hormone levels critical for puberty are normally reflected in the responses to GnRHag testing across the normal female pubertal transition. Inconsistencies between clinical and hormonal staging may arise from peripubertal cyclicity of neuroendocrine function and from excess adiposity.
- Published
- 2013
- Full Text
- View/download PDF
27. Comparison of detection of normal puberty in boys by a hormonal sleep test and a gonadotropin-releasing hormone agonist test.
- Author
-
Rosenfield RL, Bordini B, and Yu C
- Subjects
- Adiposity physiology, Adolescent, Child, Follicle Stimulating Hormone blood, Gonadotropins metabolism, Humans, Luteinizing Hormone blood, Male, Overweight blood, Overweight metabolism, Overweight physiopathology, Polysomnography statistics & numerical data, Research Design, Testosterone blood, Diagnostic Techniques, Endocrine, Gonadotropin-Releasing Hormone agonists, Gonadotropins blood, Puberty blood, Puberty metabolism, Sleep physiology
- Abstract
Context: The magnitude of sleep-related gonadotropin rise required to activate pubertal gonadal function is not established., Objective: Our objective was to determine the normal relationship between sleep-related pubertal hormone levels and pituitary-testicular responsiveness to a GnRH agonist (GnRHag) test across the pubertal transition. DESIGN/SETTING AND PARTICIPANTS: We conducted a prospective study in a General Clinical Research Center with healthy 9- to 15-yr-old volunteer boys., Interventions: INTERVENTIONS included overnight blood sampling followed by leuprolide acetate injection (10 μg/kg)., Primary Outcome Variables: LH, FSH, and testosterone levels were evaluated., Results: LH levels during sleep and post-GnRHag rose steadily during the late prepubertal years. Sleep peak LH correlated highly with the LH response to GnRHag across groups (r = 0.913). A sleep peak LH level of at least 3.7 U/liter predicted pubertal testicular activation with 100% accuracy. LH of at least 14.8 and at least 19.0 U/liter 4 h after GnRHag, respectively, predicted puberty with 100% sensitivity/94% specificity and 100% specificity/94% sensitivity. Overweight pubertal boys had transiently prolonged responses to GnRHag. FSH rose during both waking and sleeping hours during the prepubertal years, and all pubertal boys had an FSH level of at least 0.9 U/liter awake and at least 1.2 U/liter asleep. Sleep LH was more closely related than FSH to testicular size., Conclusions: These data suggest that a critical LH level during sleep (≥3.7 U/liter) heralds the onset of pubertal virilization and that this level is predictable by LH of at least 14.8-19 U/liter 4 h after GnRHag. These data also suggest that LH stimulation of testicular androgen production plays a role in stimulating testicular tubule growth once a critical level of FSH is achieved.
- Published
- 2012
- Full Text
- View/download PDF
28. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry.
- Author
-
Welt CK, Styrkarsdottir U, Ehrmann DA, Thorleifsson G, Arason G, Gudmundsson JA, Ober C, Rosenfield RL, Saxena R, Thorsteinsdottir U, Crowley WF, and Stefansson K
- Subjects
- Adolescent, Adult, Alleles, Asian People genetics, Case-Control Studies, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Guanine Nucleotide Exchange Factors, Humans, Middle Aged, Polycystic Ovary Syndrome diagnosis, Polycystic Ovary Syndrome epidemiology, Polycystic Ovary Syndrome ethnology, Polymorphism, Single Nucleotide physiology, White People statistics & numerical data, Young Adult, Death Domain Receptor Signaling Adaptor Proteins genetics, Mutation physiology, Polycystic Ovary Syndrome genetics, White People genetics
- Abstract
Context: A genome-wide association study has identified three loci (five independent signals) that confer risk for polycystic ovary syndrome (PCOS) in Han Chinese women. Replication is necessary to determine whether the same variants confer risk for PCOS in women of European ancestry., Objective: The objective of the study was to test whether these PCOS risk variants in Han Chinese women confer risk for PCOS in women of European ancestry., Design: This was a case-control study., Setting: The study was conducted at deCODE Genetics in Iceland and two academic medical centers in the United States., Patients: Cases were 376 Icelandic women and 565 and 203 women from Boston, MA, and Chicago, IL, respectively, all diagnosed with PCOS by the National Institutes of Health criteria. Controls were 16,947, 483, and 189 women not known to have PCOS from Iceland, Boston, and Chicago, respectively., Intervention: There were no interventions., Main Outcomes: Main outcomes were allele frequencies for seven variants in PCOS cases and controls., Results: Two strongly correlated Han Chinese PCOS risk variants on chromosome 9q33.3, rs10986105[C], and rs10818854[A], were replicated in samples of European ancestry with odds ratio of 1.68 (P = 0.00033) and odds ratio of 1.53 (P = 0.0019), respectively. Other risk variants at 2p16.3 (rs13405728), 2p21 (rs12468394, rs12478601, and rs13429458), and 9q33.3 (rs2479106), or variants correlated with them, did not associate with PCOS. The same allele of rs10986105 that increased the risk of PCOS also increased the risk of hyperandrogenism in women without PCOS from Iceland and demonstrated a stronger risk for PCOS defined by the National Institutes of Health criteria than the Rotterdam criteria., Conclusions: We replicated one of the five Chinese PCOS association signals, represented by rs10986105 and rs10818854 on 9q33, in individuals of European ancestry. Examination of the subjects meeting at least one of the Rotterdam criteria for PCOS suggests that the variant may be involved in the hyperandrogenism and possibly the irregular menses of PCOS.
- Published
- 2012
- Full Text
- View/download PDF
29. Overcoming burdens in the regulation of clinical research in children. Proceedings of a consensus conference, in historical context.
- Author
-
Levine RJ, Genel M, Cuttler L, Becker DJ, Nieman L, and Rosenfield RL
- Abstract
Background: Many investigators are concerned that the modes of implementation and enforcement of the federal regulations designed to protect children are unduly impeding pediatric clinical research., Objective: To assess regulatory impediments to clinical research involving children and to develop recommendations to ameliorate them., Participants: The Pediatric Endocrine Society and The Endocrine Society convened a consensus conference involving experts and stakeholders in patient-oriented research involving children and adolescents in 2008., Consensus Process: Following presentations that reviewed problematic issues around key regulations, participants divided into working groups to develop potential solutions that could be adopted at local and federal levels. Presentations to the full assembly were then debated. A writing committee then drafted a summary of the discussions and main conclusions, placing them in historical context, and submitted it to all participants for comment with the aim of developing consensus., Conclusions: Recommendations designed to facilitate the ethical conduct of research involving children addressed the interpretation of ambiguous regulatory terms such as "minimal risk" and "condition" and called for the development by professional societies of best practice primers for common research procedures that would be informative to both investigators and institutional review boards. A call was issued for improved guidance from the Office for Human Research Protections and Food and Drug Administration as well as for the development by professional societies of a process to monitor progress in improving human subject research regulation. Finally, a need for systematic research to define the nature and extent of institutional obstacles to pediatric research was recognized.
- Published
- 2011
- Full Text
- View/download PDF
30. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.
- Author
-
Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, and Ehrmann DA
- Subjects
- 17-alpha-Hydroxyprogesterone metabolism, Adrenal Glands metabolism, Adult, Body Mass Index, Dexamethasone administration & dosage, Female, Glucose Tolerance Test, Humans, Ovary metabolism, Phenotype, Prospective Studies, Regression Analysis, Testosterone pharmacology, Adrenocorticotropic Hormone blood, Androgens metabolism, Dexamethasone pharmacology, Polycystic Ovary Syndrome drug therapy
- Abstract
Background: Polycystic ovary syndrome (PCOS) patients typically have 17-hydroxyprogesterone (17OHP) hyperresponsiveness to GnRH agonist (GnRHa) (PCOS-T). The objective of this study was to determine the source of androgen excess in the one-third of PCOS patients who atypically lack this type of ovarian dysfunction (PCOS-A)., Methods: Aged-matched PCOS-T (n= 40), PCOS-A (n= 20) and controls (n= 39) were studied prospectively in a General Clinical Research Center. Short (4 h) and long (4-7 day) dexamethasone androgen-suppression tests (SDAST and LDAST, respectively) were compared in subsets of subjects. Responses to SDAST and low-dose adrenocorticotropic hormone (ACTH) were then evaluated in all., Results: Testosterone post-SDAST correlated significantly with testosterone post-LDAST and 17OHP post-GnRHa (r = 0.671-0.672), indicating that all detect related aspects of ovarian dysfunction. An elevated dehydroepiandrosterone peak in response to ACTH, which defined functional adrenal hyperandrogenism, was similarly prevalent in PCOS-T (27.5%) and PCOS-A (30%) and correlated significantly with baseline dehydroepiandrosterone sulfate (DHEAS) (r = 0.708). Functional ovarian hyperandrogenism was detected by subnormal testosterone suppression by SDAST in most (92.5%) PCOS-T, but significantly fewer PCOS-A (60%, P< 0.01). Glucose intolerance was absent in PCOS-A, but present in 30% of PCOS-T (P < 0.001). Most of the PCOS-A cases with normal testosterone suppression in response to SDAST (5/8) lacked evidence of adrenal hyperandrogenism and were obese., Conclusions: Functional ovarian hyperandrogenism was not demonstrable by SDAST in 40% of PCOS-A. Most of these cases had no evidence of adrenal hyperandrogenism. Obesity may account for most hyperandrogenemic anovulation that lacks a glandular source of excess androgen, and the SDAST seems useful in making this distinction.
- Published
- 2011
- Full Text
- View/download PDF
31. Normal pubertal development: part II: clinical aspects of puberty.
- Author
-
Bordini B and Rosenfield RL
- Subjects
- Adolescent, Adolescent Behavior physiology, Adolescent Development physiology, Child, Child Development physiology, Female, Gonadal Disorders diagnosis, Growth physiology, Humans, Male, Menstruation physiology, Menstruation Disturbances etiology, Puberty psychology, Puberty physiology
- Published
- 2011
- Full Text
- View/download PDF
32. Normal pubertal development: Part I: The endocrine basis of puberty.
- Author
-
Bordini B and Rosenfield RL
- Subjects
- Adrenal Glands metabolism, Androgens metabolism, Human Growth Hormone metabolism, Humans, Gonads metabolism, Hormones metabolism, Hypothalamus metabolism, Pituitary Gland metabolism, Puberty metabolism
- Published
- 2011
- Full Text
- View/download PDF
33. Assessing the value of treatments to increase height.
- Author
-
Cuttler L and Rosenfield RL
- Subjects
- Drug Costs, Drug Therapy, Combination, Female, Growth Disorders drug therapy, Human Growth Hormone economics, Humans, Turner Syndrome complications, Body Height drug effects, Ethinyl Estradiol administration & dosage, Growth drug effects, Human Growth Hormone therapeutic use, Turner Syndrome drug therapy
- Published
- 2011
- Full Text
- View/download PDF
34. Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome.
- Author
-
Qin K and Rosenfield RL
- Subjects
- Animals, Carbohydrate Dehydrogenases deficiency, Carbohydrate Dehydrogenases metabolism, Female, Genetic Variation, Genotype, Humans, Hyperandrogenism metabolism, Polycystic Ovary Syndrome metabolism, Carbohydrate Dehydrogenases genetics, Hyperandrogenism genetics, Mutation, Missense, Polycystic Ovary Syndrome genetics
- Abstract
Background/aim: Hexose-6-phosphate dehydrogenase (H6PD) inactivating mutations cause cortisone reductase deficiency, which manifests with hyperandrogenism unexplained by commonly used tests and, thus, mimics polycystic ovary syndrome (PCOS). The aim of this study was to screen for mutations of H6PD gene in PCOS patients with biochemical hyperandrogenemia., Methods: Direct DNA sequencing of the entire H6PD coding sequence was performed in 74 PCOS patients and 31 healthy controls. Results were confirmed by PCR-restriction fragment length polymorphism assay to determine the genotypic frequency of the variants., Results: Multiple novel missense variants were detected in the study. Two exon 2 variants (acccaggc deletion proximal to the start codon and D151A) and two exon 5 variants (R453Q and P554L) were common, occurring in 23.8%, 17.1%, 35.2%, and 16.1%, respectively. There was significant linkage disequilibrium between the exon 2 and exon 5 variants. No significant differences were observed in the genotype, allele distributions, or adrenal function tests of the variants between cases and control groups. We did not detect any reported inactivating mutations in our study., Conclusion: Although the H6PD gene is very polymorphic and missense variants are common, coding variants rarely (<1.5%) are responsible for hyperandrogenemic PCOS. We suggest that genetic studies be reserved for patients with dexamethasone-suppressible adrenal hyperandrogenism who have a discrepancy between urinary 17α-hydroxycorticoid and cortisol excretion., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
35. P450c17 deficiency caused by compound heterozygosity for two novel mutations presenting as hypotension in early infancy.
- Author
-
Gregg B, Kociolek LK, Qin K, Rosenfield RL, and Yu C
- Subjects
- Adrenal Hyperplasia, Congenital diagnosis, Amino Acid Substitution, Codon, Nonsense, Diagnosis, Differential, Disorder of Sex Development, 46,XY diagnosis, Disorder of Sex Development, 46,XY genetics, Hormone Replacement Therapy, Humans, Infant, Male, Shock genetics, Adrenal Hyperplasia, Congenital genetics, Adrenal Hyperplasia, Congenital physiopathology, Heterozygote, Hypotension genetics, Mutation, Steroid 17-alpha-Hydroxylase genetics
- Abstract
Background/aims: P450c17 deficiency is an uncommon steroidogenic disorder that typically presents as a sexually infantile adolescent phenotypic female with hypertension and hypokalemia. Although cortisol synthesis is impaired, elevated corticosterone and deoxycorticosterone ordinarily prevent adrenal insufficiency. Thus, diagnosis prior to puberty is rare. We report novel clinical features of an infant with complete P450c17 deficiency due to two novel mutations in CYP17A1., Methods: A 10-week-old, 46,XY phenotypic female presented with hypotension, developed hypokalemic hypertension post-resuscitation, then hyperkalemic hyponatremia upon weaning salt supplements. All CYP17A1 exons of the proband and parents were PCR-amplified and sequenced. Cosyntropin, GnRH agonist, and hCG tests were performed., Results: Sequencing demonstrated compound heterozygosity for two novel CYP17A1 mutations, C327dupT and C362G>A (W121X), both generating premature stop codons in exon 2 and predicting non-functional enzymes. Plasma corticosterone was very elevated, deoxycorticosterone normal, cortisol detectable, and aldosterone low-normal at baseline. Responses to cosyntropin of corticosterone and progesterone were elevated, deoxycorticosterone and aldosterone normal, cortisol subnormal, and 17α-hydroxycorticosteroid intermediates undetectable. GnRH agonist/hCG testing showed no androgenic response., Conclusion: This is the first report of P450c17 deficiency presenting in a 46,XY female infant with hypotensive shock, a state exacerbated by the atypical absence of deoxycorticosterone elevation., (Copyright © 2011 S. Karger AG, Basel.)
- Published
- 2011
- Full Text
- View/download PDF
36. Unique mode of lipogenic activation in rat preputial sebocytes.
- Author
-
Deplewski D, Qin K, Ciletti N, and Rosenfield RL
- Abstract
Lipoprotein delivery of fatty acids and cholesterol is linked with peroxisome proliferator-activated receptor (PPAR) activation in adipocytes and macrophages. We postulated that similar interactions exist in sebaceous epithelial cells (sebocytes) in which PPAR activation induces differentiation. High-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) markedly enhanced sebocyte differentiation above that found with PPAR agonists and were more potent than explicable by their lipid content. The PPARγ antagonist GW5393 reduced sebocyte differentiation to all PPAR isoform agonists, HDL and VLDL, suggesting that the lipoprotein effect on differentiation occurs partially through activation of PPARγ. Furthermore, we found that sebocytes expressed a unique pattern of lipogenic genes. Our results demonstrate that HDL and VLDL are the most potent inducers of sebocyte differentiation tested to date, and these actions are partially inhibited by PPAR antagonists. This suggests that substrates provided by lipoproteins are targeted to sebocytes and affect their own disposition via PPAR activation.
- Published
- 2011
- Full Text
- View/download PDF
37. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.
- Author
-
Rosenfield RL and Bordini B
- Subjects
- Animals, Female, Humans, Luteinizing Hormone physiology, Male, Neurosecretory Systems physiology, Polycystic Ovary Syndrome physiopathology, Sexual Maturation physiology, Aging physiology, Androgens physiology, Gonadotropins biosynthesis, Obesity physiopathology, Puberty physiology
- Abstract
Optimal fat mass is necessary for normal gonadotropin levels in adults, and both undernutrition and overnutrition suppress gonadotropins: thus, the gonadotropin response to relative adipose mass is biphasic. Adult obesity is associated with blunted luteinizing hormone (LH) pulse amplitude that is partially attributable to increased LH clearance rate. Testosterone appears to have a biphasic effect on gonadotropin production in females. Moderate elevations of testosterone appear to stimulate LH production at both the hypothalamic and pituitary level, while very high levels of testosterone suppress LH. Thus, obesity per se appears to suppress gonadotropin production, and moderate hyperandrogenemia in women appears to stimulate LH. The ordinary hypergonadotropic hyperandrogenism of obese women appears to be an exception to this model because it is usually due to polycystic ovary syndrome (PCOS), a condition in which intrinsic functional ovarian hyperandrogenism and excess adiposity share a common origin that involves insulin-resistant hyperinsulinemia. LH elevation seems to be secondary to hyperandrogenemia and is absent in the most obese cases. Overweight early pubertal girls have significant blunting of sleep-related LH production, which is the first hormonal change of puberty. The data are compatible with the possibility that excess adiposity may paradoxically subtly suppress hypothalamic-pituitary-gonadal function in early puberty although it is known to contribute to the early onset of puberty., (Copyright © 2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
38. Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency.
- Author
-
Zimmer CA, Ehrmann DA, and Rosenfield RL
- Subjects
- Adolescent, Adult, Dosage Forms, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Hypogonadism etiology, Male, Periodicity, Predictive Value of Tests, Prognosis, Young Adult, Gonadotropin-Releasing Hormone agonists, Gonadotropins deficiency, Hypogonadism diagnosis, Leuprolide administration & dosage
- Abstract
Objective: To determine if intermittent, low-dose, short-acting gonadotropin-releasing hormone agonist (GnRH-agonist) administration sufficiently up-regulates pituitary-gonadal function in gonadotropin deficiency to be of diagnostic or therapeutic value., Design: Case-control study., Setting: General clinical research center., Patient(s): Normal adult volunteers and gonadotropin-deficiency patients., Intervention(s): Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year., Main Outcome Measure(s): Levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroid responses., Result(s): In normal men and women, low-dose GnRH-agonist repetitively transiently stimulated gonadotropins in a gender-dimorphic manner. In congenitally gonadotropin-deficient men (n = 6) and women (n = 1), none of whom had a normal LH response to an initial GnRH-agonist test dose, this regimen consistently stimulated LH to the normal baseline range within 2 weeks. Long-term GnRH-agonist administration to a partially gonadotropin-deficient man did not alleviate hypogonadism, however. Women with hypothalamic amenorrhea (n = 2) responded normally to a single GnRH-agonist injection; however, repeated dosing did not seem to induce the normal priming effect., Conclusion(s): The subnormal LH response to GnRH-agonist in patients with congenital gonadotropin deficiency normalized in response to repetitive intermittent GnRH-agonist administration but not sufficiently to improve hypogonadism. Hypothalamic amenorrhea patients lacked the priming response to repeated GnRH-agonist but otherwise had normal hormonal responses to GnRH-agonist. We conclude that intermittent administration of a short-acting GnRH-agonist is of potential diagnostic value in distinguishing hypothalamic from pituitary causes of gonadotropin deficiency., (Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
39. LH Dynamics in Overweight Girls with Premature Adrenarche and Slowly Progressive Sexual Precocity.
- Author
-
Bordini B, Littlejohn E, and Rosenfield RL
- Abstract
Background. Excess adiposity and premature adrenarche (PA) are risk factors for the development of polycystic ovary syndrome (PCOS). Methods. Girls with slowly progressive precocious breast development, who were overweight and had PA (SPPOPA, 6.2-8.2 years, n = 5), overweight PA (6.6-10.8 years, n = 7), and overweight premenarcheal controls (OW-PUB, 10.6-12.8 years, n = 8) underwent hormonal sleep testing and GnRH agonist (GnRHag) and ACTH tests. Results. Despite an insignificant sleep-related increase in LH and prepubertal baseline hormone levels, SPPOPA peak LH and estradiol responses to GnRHag were intermediate between those of PA and OW-PUB, the LH being significantly different from both. Conclusions. GnRHag tests indicate that SPPOPA is a slowly progressive form of true puberty with blunted LH dynamics. These results argue against the prepubertal hyperandrogenism of excess adiposity or PA enhancing LH secretion or causing ovarian hyperandrogenism prior to menarche. Excess adiposity may contribute to both the early onset and slow progression of puberty.
- Published
- 2010
- Full Text
- View/download PDF
40. KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women.
- Author
-
Du X, Rosenfield RL, and Qin K
- Subjects
- 17-Hydroxysteroid Dehydrogenases metabolism, 3-Hydroxysteroid Dehydrogenases, Aldo-Keto Reductase Family 1 Member C3, Animals, Base Sequence, Cells, Cultured, Female, Humans, Hydroxyprostaglandin Dehydrogenases, Insulin pharmacology, Lipid Metabolism genetics, Molecular Sequence Data, Promoter Regions, Genetic physiology, Rats, Sequence Homology, Nucleic Acid, Sex Factors, Transcription Factors physiology, Transcriptional Activation drug effects, Transcriptional Activation physiology, 17-Hydroxysteroid Dehydrogenases genetics, Adipose Tissue metabolism, Gene Expression Regulation, Enzymologic drug effects, Kruppel-Like Transcription Factors physiology, Nuclear Proteins physiology, Testosterone metabolism
- Abstract
Context: Kruppel-like factor 15 (KLF15) is a newly discovered transcription factor that plays an important role in glucose homeostasis and lipid accumulation in cells. We present evidence for KLF15 as a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene (HSD17B5) and its potential role in the pathogenesis of hyperandrogenism., Objective: The aim was to investigate the molecular mechanism of HSD17B5 regulation., Methods: Diverse molecular biology techniques were used., Design and Results: We identified a KLF15 binding site in the HSD17B5 promoter by using luciferase promoter constructs, EMSA, and chromatin immunoprecipitation assays. Overexpression of KLF15 increased HSD17B5 promoter activity and testosterone formation at least 3-fold in cultured H295R cells. Insulin increased KLF15 mRNA expression according to real-time RT-PCR and increased HSD17B5 promoter activity according to luciferase assays. KLF15 overexpression in combination with insulin, glucocorticoid, and cAMP stimulated adipogenesis in H295R cells. In silico and RT-PCR analyses showed that the KLF15 gene promoter undergoes alternative splicing in a tissue-specific manner. Comparison of the HSD17B5 promoter in seven different species revealed that the KLF15 binding site has no human homolog in species other than orangutans., Conclusions: KLF15 is potentially a novel link between the regulation of testosterone production and fat stores by insulin in humans.
- Published
- 2009
- Full Text
- View/download PDF
41. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population.
- Author
-
Mortensen M, Ehrmann DA, Littlejohn E, and Rosenfield RL
- Subjects
- 17-alpha-Hydroxyprogesterone blood, Adolescent, Adrenocorticotropic Hormone blood, Adult, Anovulation etiology, Body Mass Index, Child, Preschool, Dehydroepiandrosterone Sulfate blood, Estradiol blood, Female, Follicle Stimulating Hormone blood, Gonadotropin-Releasing Hormone agonists, Humans, Hyperandrogenism etiology, Luteinizing Hormone blood, Ovary diagnostic imaging, Ovary physiopathology, Pelvis diagnostic imaging, Phenotype, Polycystic Ovary Syndrome diagnostic imaging, Prospective Studies, Testosterone blood, Ultrasonography, Young Adult, Polycystic Ovary Syndrome physiopathology
- Abstract
Context/objective: Our objective was to determine the ovarian function of asymptomatic volunteers with a polycystic ovary (V-PCO)., Participants: Non-hirsute eumenorrheic V-PCO (n = 32) and volunteers with ultrasonographically normal ovaries (V-NO) (n = 21) were compared with one another and with polycystic ovary syndrome (PCOS) patients who met National Institute of Health criteria (n = 90). DESIGN/SETTING/INTERVENTIONS: GnRH agonist (GnRHag), ACTH, and oral glucose tolerance tests were prospectively performed in a General Clinical Research Center., Results: The distribution of 17-hydroxyprogesterone (17OHP) responses to GnRHag of V-PCO formed a distinct population intermediate between that of V-NO, the reference population, and PCOS. Nevertheless, the V-PCO population was heterogeneous. There were 53% (seventeen of 32) that were functionally normal, with 17OHP responses and free testosterone levels like V-NO. A total of 25% (eight of 32) had an elevated free testosterone, thus meeting Rotterdam criteria for PCOS; one third of these had 17OHP hyperresponsiveness to GnRHag testing. The remaining 22% (seven of 32) had 17OHP hyperresponsiveness to GnRHag, but normal free testosterone. Of PCOS, 69% had elevated 17OHP hyperresponsiveness to GnRHag. Ovarian volume correlated significantly with 17OHP responses only in PCOS, accounting for just 10% of the variance., Conclusions: Many asymptomatic volunteers have a PCO. They are a distinct, but heterogeneous, population with respect to ovarian function, ranging from normal (53%) to occult PCOS by Rotterdam criteria (25%). Nearly one quarter (22%) had the typical PCOS type of ovarian dysfunction without hyperandrogenemia, termed a "dysregulated PCO"; they or their offspring may be at risk for PCOS. Ovarian ultrasonographic characteristics must be considered when establishing norms for ovarian function.
- Published
- 2009
- Full Text
- View/download PDF
42. Characterization of functionally typical and atypical types of polycystic ovary syndrome.
- Author
-
Hirshfeld-Cytron J, Barnes RB, Ehrmann DA, Caruso A, Mortensen MM, and Rosenfield RL
- Subjects
- Adult, Chorionic Gonadotropin, Cohort Studies, Female, Follicle Stimulating Hormone, Gonadal Steroid Hormones blood, Granulosa Cells physiology, Humans, Inhibins blood, Ovarian Follicle physiology, Phenotype, Steroids biosynthesis, Theca Cells physiology, Young Adult, Polycystic Ovary Syndrome physiopathology
- Abstract
Context: The typical polycystic ovary syndrome (PCOS) phenotype includes 17-hydroxyprogesterone (17OHP) hyperresponsiveness to GnRH agonist (GnRHag) testing. Functionally atypical PCOS lacks this feature., Objective: The hypothesis was tested that the typical PCOS ovarian dysfunction results from intrinsically increased sensitivity to LH/human chorionic gonadotropin (hCG) due to a flaw in FSH action. PARTICIPANTS/DESIGN/INTERVENTIONS/MAIN OUTCOME MEASURES: After phenotyping a cohort of 60 women, steroid and inhibin-B responses to gonadotropins were evaluated in representative typical (n = 7) and atypical (n = 5) PCOS and healthy controls (n = 8). Submaximal hCG testing before and after an FSH test dose was performed in random order before and after prolonged ovarian suppression by depot GnRHag., Setting: The study was performed at a Clinical Research Center., Results: Of our PCOS cohort, 68% were the typical type. Typical PCOS had 17OHP hyperresponsiveness and, unlike controls, significant androgen and estradiol responses to hCG. FSH increased inhibin-B and did not inhibit free testosterone or enhance estradiol responsiveness to hCG, all unlike controls. After ovarian suppression, 17OHP, androstenedione, and inhibin-B responsiveness to gonadotropin testing persisted. Atypical PCOS had significantly higher body mass index but lower ovarian volume and plasma free testosterone than typical PCOS. Steroid responses to hCG were insignificant and similar to controls. FSH suppressed free testosterone but stimulated inhibin-B. The estradiol level after combined hCG-FSH was subnormal. Free testosterone was less GnRHag suppressible than in typical PCOS., Conclusions: Typical PCOS is characterized by intrinsic ovarian hypersensitivity to hCG to which excessive paracrine FSH signaling via inhibin-B may contribute. Atypical PCOS is due to a unique type of ovarian dysfunction that is relatively gonadotropin hyposensitive.
- Published
- 2009
- Full Text
- View/download PDF
43. Consensus statement on the use of gonadotropin-releasing hormone analogs in children.
- Author
-
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, and Wit JM
- Subjects
- Adolescent, Body Height drug effects, Bone Density drug effects, Child, Female, Humans, Hypothyroidism epidemiology, Luteinizing Hormone pharmacology, Nafarelin pharmacology, Organ Size, Ovary pathology, Polycystic Ovary Syndrome chemically induced, Puberty, Precocious epidemiology, Puberty, Precocious pathology, Puberty, Precocious psychology, Uterus pathology, Gonadotropin-Releasing Hormone analogs & derivatives, Puberty, Precocious drug therapy
- Abstract
Objective: Gonadotropin-releasing hormone analogs revolutionized the treatment of central precocious puberty. However, questions remain regarding their optimal use in central precocious puberty and other conditions. The Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology convened a consensus conference to review the clinical use of gonadotropin-releasing hormone analogs in children and adolescents., Participants: When selecting the 30 participants, consideration was given to equal representation from North America (United States and Canada) and Europe, an equal male/female ratio, and a balanced spectrum of professional seniority and expertise., Evidence: Preference was given to articles written in English with long-term outcome data. The US Public Health grading system was used to grade evidence and rate the strength of conclusions. When evidence was insufficient, conclusions were based on expert opinion., Consensus Process: Participants were put into working groups with assigned topics and specific questions. Written materials were prepared and distributed before the conference, revised on the basis of input during the meeting, and presented to the full assembly for final review. If consensus could not be reached, conclusions were based on majority vote. All participants approved the final statement., Conclusions: The efficacy of gonadotropin-releasing hormone analogs in increasing adult height is undisputed only in early-onset (girls <6 years old) central precocious puberty. Other key areas, such as the psychosocial effects of central precocious puberty and their alteration by gonadotropin-releasing hormone analogs, need additional study. Few controlled prospective studies have been performed with gonadotropin-releasing hormone analogs in children, and many conclusions rely in part on collective expert opinion. The conference did not endorse commonly voiced concerns regarding the use of gonadotropin-releasing hormone analogs, such as promotion of weight gain or long-term diminution of bone mineral density. Use of gonadotropin-releasing hormone analogs for conditions other than central precocious puberty requires additional investigation and cannot be suggested routinely.
- Published
- 2009
- Full Text
- View/download PDF
44. Blunted sleep-related luteinizing hormone rise in healthy premenarcheal pubertal girls with elevated body mass index.
- Author
-
Bordini B, Littlejohn E, and Rosenfield RL
- Subjects
- Adolescent, Adrenocorticotropic Hormone blood, Child, Female, Follicle Stimulating Hormone blood, Gonadotropin-Releasing Hormone blood, Gonadotropins, Humans, Male, Wakefulness, Body Mass Index, Luteinizing Hormone blood, Obesity blood, Overweight blood, Puberty physiology, Sleep physiology
- Abstract
Objective: Our objective was to determine whether excessive adiposity is associated with alteration of the normal hormonal changes of early pubertal girls., Design and Participants: Healthy 6.4- to 9.5-yr-old, prepubertal (PRE, n = 20) and 9.4- to 13.0-yr-old pubertal premenarcheal volunteers (PUB, n = 20) were divided into excessive-weight (EW) or normal-weight (NW) groups according to the 85th percentile body mass index. INTERVENTIONS AND SETTING: Overnight blood sampling; GnRH agonist (GnRHag), low-dose ACTH, oral glucose tolerance tests, and pelvic ultrasonograms were performed in our Clinical Research Center., Results: EW girls were similar in age and baseline and ACTH- and GnRHag-stimulated androgen levels to stage-matched NW girls. However, the sleep-related LH rise was blunted in EW-PUB girls compared with NW-PUB girls. The sleep-related rise of mean LH in EW-PUB [0.68 +/- 0.35 (sem) U/liter] was insignificant, less than that of NW-PUB (2.1 +/- 0.45, P < 0.05) and not significantly different from that of PRE girls (0.08+/-0.03). EW-PUB had slower LH pulse frequency and a lower rise in LH pulse amplitude during sleep than NW-PUB girls (both P < 0.05). Overnight FSH patterns paralleled LH patterns, whereas estradiol levels were similar in stage-matched NW and EW groups, differing between stages as expected. Early morning and peak LH, FSH, and estradiol responses to GnRHag were similar in EW-PUB and NW-PUB and significantly greater than those of PRE girls., Conclusions: Healthy EW-PUB girls have significantly blunted sleep-related LH production. These data suggest that excess adiposity, in the absence of sex steroid excess, may subtly suppress hypothalamic-pituitary-gonadal function in premenarcheal pubertal girls.
- Published
- 2009
- Full Text
- View/download PDF
45. What every physician should know about polycystic ovary syndrome.
- Author
-
Rosenfield RL
- Subjects
- Female, Humans, Risk Factors, Hirsutism diagnosis, Hirsutism epidemiology, Hirsutism therapy, Polycystic Ovary Syndrome diagnosis, Polycystic Ovary Syndrome epidemiology, Polycystic Ovary Syndrome therapy
- Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine cause of hirsutism, acne, and pattern alopecia. It is a heterogeneous syndrome of hyperandrogenic anovulation that is typically due to intrinsic ovarian dysfunction, which is often aggravated by insulin-resistant hyperinsulinemia with its risks of diabetes mellitus and metabolic syndrome and their complications. Because there are many pitfalls to androgen assays, evaluation for hyperandrogenemia is suggested in women with moderate or severe hirsutism or hirsutism equivalents, menstrual irregularity, acanthosis nigricans, or intractable obesity. An endocrinologic work-up is necessary to rule out other hyperandrogenic disorders that require specific therapy (e.g., virilizing tumors, nonclassic congenital adrenal hyperplasia, hyperprolactinemia, and Cushing's syndrome). Ultrasonography helps in the differential diagnosis and may demonstrate the polycystic ovaries that have recently been vetted as an alternative to oligo-anovulation as a diagnostic criterion. Management of PCOS is determined by symptomatology. For those women not desiring pregnancy, the most common therapies are oral contraceptive pills, antiandrogens (contraindicated in the absence of adequate contraception), and insulin-lowering treatments (which have little effect on hirsutism).
- Published
- 2008
- Full Text
- View/download PDF
46. Perspectives on the endocrine society clinical practice guideline for the evaluation and treatment of women with hirsutism.
- Author
-
Rosenfield RL
- Subjects
- Androgen Antagonists therapeutic use, Hirsutism blood, Humans, Sensitivity and Specificity, Testosterone blood, Hirsutism diagnosis, Hirsutism drug therapy, Practice Guidelines as Topic
- Published
- 2008
47. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.
- Author
-
Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM, and Swiglo BA
- Subjects
- Clinical Trials as Topic, Evidence-Based Medicine, Female, Humans, Premenopause, Hirsutism diagnosis, Hirsutism therapy
- Abstract
Objective: Our objective was to develop clinical practice guidelines for the evaluation and treatment of hirsutism in premenopausal women., Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, two methodologists, and a medical writer. The Task Force received no corporate funding or remuneration., Evidence: Systematic reviews of available evidence were used to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group criteria to describe both the quality of evidence and the strength of recommendations. We used "recommend" for strong recommendations, and "suggest" for weak recommendations., Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the Task Force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Core Committee (CACC), and Council. The version approved by the CGS and CACC was placed on The Endocrine Society's Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes., Conclusions: We suggest testing for elevated androgen levels in women with moderate or severe hirsutism or hirsutism of any degree when it is sudden in onset, rapidly progressive, or associated with other abnormalities such as menstrual dysfunction, obesity, or clitoromegaly. For women with patient-important hirsutism despite cosmetic measures, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For women who choose hair removal therapy, we suggest laser/photoepilation.
- Published
- 2008
- Full Text
- View/download PDF
48. Improving balance in regulatory oversight of research in children and adolescents: a clinical investigator's perspective.
- Author
-
Rosenfield RL
- Subjects
- Adolescent, Adult, Child, Conflict of Interest, Government Regulation, Humans, Risk Assessment, Biomedical Research legislation & jurisprudence, Research Subjects legislation & jurisprudence
- Abstract
The current regulatory environment, designed to protect children, imposes barriers to research in children that are a deterrent to high-quality clinical research in minors. This article summarizes the special procedures necessary to obtain approval for research in healthy children that poses more than minimal risk according to the code of federal regulations (45 CFR 46.407 and 21 CFR 50.54). The operational realities of the process are illustrated by the case of the most recent research protocol to be reviewed under these rules. The current process poses obstacles to future studies of complex research questions in children and adolescents that require unaffected controls, such as the relationship of adolescent anovulatory disorders to adult illness. It is concluded that current regulatory procedures, while protecting children, increase the potential for the neglect of important research needs of children and are a disincentive to pursuit of a career in clinical research for young clinicians. Suggestions are made for improving the balance between the need for research in children and adolescents and its regulation.
- Published
- 2008
- Full Text
- View/download PDF
49. Clinical review: Identifying children at risk for polycystic ovary syndrome.
- Author
-
Rosenfield RL
- Subjects
- Adolescent, Adrenarche physiology, Anovulation etiology, Child, Female, Humans, Hypothalamus physiopathology, Models, Biological, Obesity etiology, Ovary physiopathology, Pituitary Gland physiopathology, Polycystic Ovary Syndrome congenital, Polycystic Ovary Syndrome etiology, Polycystic Ovary Syndrome physiopathology, Puberty, Precocious etiology, Risk Factors, Polycystic Ovary Syndrome diagnosis
- Abstract
Context: Polycystic ovary syndrome (PCOS) appears to arise as a complex trait with contributions from both heritable and nonheritable factors. Polygenic influences appear to account for about 70% of the variance in pathogenesis. In view of this evidence for congenital contributions to the syndrome, childhood manifestations may be expected., Objective: The objective has been to review the evidence that risk factors for PCOS can be recognized in childhood., Design: This study consisted of screening of the PCOS literature for articles pertaining to potential childhood and adolescent antecedents., Results: Congenital virilizing disorders; above average or low birth weight for gestational age; premature adrenarche, particularly exaggerated adrenarche; atypical sexual precocity; or intractable obesity with acanthosis nigricans, metabolic syndrome, and pseudo-Cushing syndrome or pseudo-acromegaly in early childhood have been identified as independent prepubertal risk factors for the development of PCOS. During adolescence, PCOS may masquerade as physiological adolescent anovulation. Asymptomatic adolescents with a polycystic ovary occasionally (8%) have subclinical PCOS but often (42%) have a subclinical PCOS type of ovarian dysfunction, the prognosis for which is unclear., Conclusion: Identifying children at risk for PCOS offers the prospect of eventually preventing some of the long-term complications associated with this syndrome once our understanding of the basis of the disorder improves.
- Published
- 2007
- Full Text
- View/download PDF
50. KAL1 mutations are not a common cause of idiopathic hypogonadotrophic hypogonadism in humans.
- Author
-
Bhagavath B, Xu N, Ozata M, Rosenfield RL, Bick DP, Sherins RJ, and Layman LC
- Subjects
- Adult, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, Genotype, Humans, Kallmann Syndrome genetics, Male, Phenotype, Polymorphism, Single-Stranded Conformational, Risk Factors, Extracellular Matrix Proteins genetics, Hypogonadism genetics, Mutation, Nerve Tissue Proteins genetics
- Abstract
Hypogonadotrophic hypogonadism results in the absence of puberty and if left untreated leads to infertility. Mutations in KAL1 are known to account for some of the cases of Kallmann syndrome. The aim of this study was to determine the prevalence of KAL1 mutations in a large number of patients with idiopathic hypogonadotrophic hypogonadism (IHH). One hundred and thirty eight patients (109 males and 29 females) with IHH were studied for mutations in KAL1. DNA from these patients was subjected to denaturing gradient gel electrophoresis or single strand conformation polymorphism to identify mutations. Sequencing was performed to confirm mutations detected. Four mutations were found in 109 males (3.7%). All four mutations were in anosmic/hyposmic men making the prevalence 4/63 (6.3%) in this group of patients. No mutations were found in the 29 female patients. KAL1 mutations are an uncommon cause of Kallmann syndrome.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.